Amgen Inc. (AMGN)
NASDAQ • Healthcare
May 20, 2026 at 16:00 UTC
About Amgen Inc.
Amgen Inc. is a biotechnology company focused on discovering, developing, and marketing medicines for serious illnesses across immunology, oncology, cardiometabolic disease, and other therapeutic areas. The company’s expertise spans biologics, targeted therapies, and biosimilars, supported by research platforms in protein engineering and human genetics. Commercial operations include physician education, patient access programs, and collaborations with health systems that emphasize safe and appropriate use of therapies. Amgen distributes products in North America, Europe, and additional regions through a mix of direct channels and partners. Positioned within the healthcare sector, the company’s work reflects the growing role of biotechnology in addressing complex medical needs and advancing precision approaches to treatment.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Amgen Inc.'s Technical Indicators Summary
Amgen displays a neutral technical picture with price hovering around short-term averages while remaining above the 200-day, creating mixed signals across timeframes. Momentum measures are generally muted and MACD is flat to slightly negative, and ADX near 15 implies the market lacks clear trend strength. OBV is positive and VWAP sits slightly below the current price, which together hint at steady accumulation but not strong conviction. Volatility is modest, so price action may remain range-bound until a decisive catalyst emerges. Technical takeaway: Neutral.
| Indicator | Value |
|---|---|
RSI (14) | 44.55 |
Stochastic %K (14, 3, 3) | 36.60 |
CCI (20) | -42.51 |
WPR (14) | -38.79 |
Momentum (10) | 0.41 |
MFI | 47.81 |
MACD Level (12, 26) | -4.76 |
Bollinger Bands | $320.12 - $348.27 |
ATR (14) | $7.70 (2.32%) |
ADX (14) | 15.03 |
OBV | 50,507,404 |
VWAP | $329.64 |
Classic Pivot Point | $328.02 |
Fibonacci Pivot Point | $328.02 |
Simple Moving Averages | $326.76 - $349.83(5 indicators) |
Exponential Moving Averages | $325.50 - $342.34(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Into the close, AMGN retained a slight positive bias, with the 0.25% gap from yesterday leaving it near 331.57. Into the bell, a flat sector move (-0.12%) kept the backdrop muted. AMGN drifts higher on strong quarterly results and dividend, with a cautious sector backdrop capping upside.
Price Change
from $331.61 close
+$0.05
Trading Volume
Above avg 2.6M
3.4M
vs S&P 500 Today
Moderate Underperformance
-0.23%
52-Week Position
Mid-range
51.6%
Updated: May 20, 2026 at 20:04 UTC
Quote Summary
AMGN Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Institutions Shift Positions in Major Blue-Chip Stocks
April 17, 2026
Amgen Rides Renewed GLP-1 Obesity Momentum
April 9, 2026
Amgen and Gilead Face Conflicting Valuation Signals
March 12, 2026